Myasthenia gravis induced by avelumab

References

• Sharpe AH , WherryEJ , AhmedR , FreemanGJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol.8(3), 239–245 (2007).
   PubMed Web of Science ®Google Scholar
• Keir ME , ButteMJ , FreemanGJ , SharpeAH. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol.26, 677–704 (2008).
   PubMed Web of Science ®Google Scholar
• Iwai Y , IshidaM , TanakaY , OkazakiT , HonjoT , MinatoN. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA99(19), 12293–12297 (2002).
   PubMed Web of Science ®Google Scholar
• Gong J , Chehrazi-RaffleA , ReddiS , SalgiaR. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J. Immunother. Cancer6(1), 8 (2018).
   PubMed Web of Science ®Google Scholar
• Naidoo J , PageDB , LiBTet al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann. Oncol.26(12), 2375–2391 (2015).
   PubMed Web of Science ®Google Scholar
• Postow MA , SidlowR , HellmannMD. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med.378(2), 158–168 (2018).
   PubMed Web of Science ®Google Scholar
• Nishimura H , OkazakiT , TanakaYet al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science291(5502), 319–322 (2001).
   PubMed Web of Science ®Google Scholar
• Klocke K , SakaguchiS , HolmdahlR , WingK. Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood. Proc. Natl Acad. Sci. USA113(17), E2383–E2392 (2016).
   PubMed Web of Science ®Google Scholar
• Zimmer L , GoldingerSM , HofmannLet al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur. J. Cancer60, 210–225 (2016).
   PubMed Web of Science ®Google Scholar
• Makarious D , HorwoodK , CowardJIG. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur. J. Cancer82, 128–136 (2017).
   PubMed Web of Science ®Google Scholar
• Puwanant A , IsfortM , LacomisD , ZivkovicSA. Clinical spectrum of neuromuscular complications after immune checkpoint inhibition. Neuromuscul. Disord.29(2), 127–133 (2019).
   PubMed Web of Science ®Google Scholar
• Gilhus NE , VerschuurenJJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol.14(10), 1023–1036 (2015).
   PubMed Web of Science ®Google Scholar
• Reyes-Bueno JA , Rodriguez-SantosL , Serrano-CastroPJ. [Myasthenia gravis induced by inmuno checkpoints inhibitors: first case report secondary to avelumab therapy and review of published cases]. Rev. Neurol.68(8), 333–338 (2019).
   PubMed Web of Science ®Google Scholar
• Brahmer JR , TykodiSS , ChowLQet al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med.366(26), 2455–2465 (2012).
   PubMed Web of Science ®Google Scholar
• Antonia S , GoldbergSB , BalmanoukianAet al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, Phase Ib study. Lancet Oncol.17(3), 299–308 (2016).
   PubMed Web of Science ®Google Scholar
• Carrera W , BaartmanBJ , KosmorskyG. A case report of drug-induced myopathy involving extraocular muscles after combination therapy with tremelimumab and durvalumab for non-small cell lung cancer. Neuroophthalmology41(3), 140–143 (2017).
   PubMed Web of Science ®Google Scholar
• John S , AntoniaSJ , RoseTAet al. Progressive hypoventilation due to mixed CD8(+) and CD4(+) lymphocytic polymyositis following tremelimumab - durvalumab treatment. J. Immunother. Cancer5(1), 54 (2017).
   PubMedGoogle Scholar
• Anquetil C , SalemJE , Lebrun-VignesBet al. Immune checkpoint inhibitor-associated myositis. Circulation138(7), 743–745 (2018).
   PubMed Web of Science ®Google Scholar
• Mongiovi PC , ElsheikhB , LawsonVH , KisselJT , ArnoldWD. Neuromuscular junction disorders mimicking myopathy. Muscle Nerve50(5), 854–856 (2014).
   PubMed Web of Science ®Google Scholar
• Kao JC , LiaoB , MarkovicSNet al. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol.74(10), 1216–1222 (2017).
   PubMed Web of Science ®Google Scholar
• Latchman Y , WoodCR , ChernovaTet al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol.2(3), 261–268 (2001).
   PubMed Web of Science ®Google Scholar
• Yuen C , ReidP , ZhangZ , SolivenB , LukeJ . RezaniaK Facial Palsy Induced by Checkpoint Blockade: A Single Center Retrospective Study. J Immunother42(3), 94–96 (2019).
   PubMed Web of Science ®Google Scholar
• Wiendl H , MitsdoerfferM , SchneiderDet al. Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies. FASEB J.17(13), 1892–1894 (2003).
   PubMedGoogle Scholar
• Iwasa K , YoshikawaH , FurukawaY , YamadaM. Programmed cell death ligand 1 expression is upregulated in the skeletal muscle of patients with myasthenia gravis. J. Neuroimmunol.325, 74–78 (2018).
   PubMed Web of Science ®Google Scholar
• Sakthivel P , RamanujamR , WangXB , PirskanenR , LefvertAK. Programmed death-1: from gene to protein in autoimmune human myasthenia gravis. J. Neuroimmunol.193(1-2), 149–155 (2008).
   PubMed Web of Science ®Google Scholar